Hereditary Angioedema Market Analysis 2026: Market Size, Growth Trends And Industry Outlook

Hereditary Angioedema Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Hereditary Angioedema Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?

The hereditary angioedema market has experienced robust growth over the past few years. Projections indicate it will expand from $2.81 billion in 2025 to reach $3.04 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 8.2%. Historically, this expansion has been driven by factors such as a rise in clinical awareness concerning rare genetic disorders, the widespread availability of plasma-derived c1 esterase inhibitors, the proliferation of specialty treatment centers, enhanced diagnostic precision for hae, and burgeoning patient advocacy efforts.

The hereditary angioedema market is anticipated to experience robust expansion over the coming years. It is projected to achieve a valuation of $4.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This projected growth can be attributed to the proliferation of novel oral and subcutaneous therapies, increasing investment in the development of drugs for rare diseases, the rising integration of personalized medicine strategies, the expansion of genetic screening initiatives, and enhanced long-term disease management approaches. Significant trends during the forecast period encompass the growing adoption of targeted bradykinin therapies, an increase in the use of prophylactic treatment regimens, a heightened focus on early genetic diagnosis, the broadened availability of home-based self-administration therapies, and the refinement of patient-centric treatment methodologies.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=48517837&type=smp&name=Hereditary%20Angioedema%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Hereditary Angioedema Market Growth Drivers: What’s Behind The Acceleration?

An increasing occurrence of rare diseases is anticipated to boost the expansion of the hereditary angioedema market in the future. These conditions, also termed orphan diseases, are medical ailments impacting a minor segment of the populace. Their rising frequency stems from several influences, including advancements in medical research, shifts in population demographics, and ecological effects. Hereditary angioedema (HAE) stands out as a critical rare disease, emphasizing the necessity for specialized interventions and public understanding because of its potentially fatal swelling attacks. Its infrequent occurrence and genetic basis underscore the importance of prompt diagnosis and specific treatments for efficient management and enhanced patient results. For illustration, in January 2025, information from The American Cancer Society, a US-based professional organization, indicates that in 2025, around 59,660 new diagnoses of oral cavity and oropharyngeal cancer are foreseen, with an estimated 12,770 individuals predicted to succumb to these forms of cancer. Consequently, the expanding occurrence of rare diseases is fueling the development of the hereditary angioedema market.

Hereditary Angioedema Market Segment Trends And Revenue Contributors

The hereditary angioedema market covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I, Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis, On-demand

3) By Drug Class: C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, Kallikrein Inhibitors, Other Drug Classes

4) By Route Of Administration: Subcutaneous, Intravenous, Oral

5) By Distribution channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency, Low C1-Inhibitor Levels

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, Genetic Mutations In SERPING1 Gene

Hereditary Angioedema Market Trends Redefining Industry Growth

Major companies in the hereditary angioedema market are developing innovative products, such as oral plasma kallikrein inhibitors, to offer patients more convenient and effective on-demand treatment options. Oral plasma kallikrein inhibitors are medications that block plasma kallikrein to prevent excessive bradykinin production, primarily utilized for treating hereditary angioedema. For instance, in September 2024, KalVista Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the FDA had accepted its new drug application (NDA) for sebetralstat. This investigational oral plasma kallikrein inhibitor is intended for the immediate treatment of hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and older. Sebetralstat introduces a new treatment strategy by targeting and inhibiting plasma kallikrein activity. The acceptance of the NDA represents a significant milestone toward potential approval and commercialization.

Hereditary Angioedema Market Competitive Landscape: Which Companies Lead The Industry?

Major companies operating in the hereditary angioedema market are Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc.

View The Full Hereditary Angioedema Market Report:

https://thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Hereditary Angioedema Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the hereditary angioedema market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model